Suehnholz, S. P. et al. Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov. 14, 49–65 (2024).
Article CAS PubMed Google Scholar
Yin, X.-J., Wang, R., Shen, H.-S., Jin, J. & Zhu, H.-H. At what point are long-term (>5 years) survivors of APL safe? A study from the SEER database. Cancers 15, 575 (2023).
Article PubMed PubMed Central Google Scholar
Church, D. N. et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J. Natl Cancer Inst. 107, 402 (2015).
Arber, D. A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200–1228 (2022).
Article CAS PubMed PubMed Central Google Scholar
Schrader, K. A. et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2, 104–111 (2016).
Article PubMed PubMed Central Google Scholar
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015).
Article PubMed PubMed Central Google Scholar
Mandelker, D. et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann. Oncol. 30, 1221–1231 (2019).
Article CAS PubMed PubMed Central Google Scholar
Stadler, Z. K. et al. Therapeutic implications of germline testing in patients with advanced cancers. J. Clin. Oncol. 39, 2698–2709 (2021).
Article CAS PubMed PubMed Central Google Scholar
Tang, X., Berger, M. F. & Solit, D. B. Precision oncology: current and future platforms for treatment selection. Trends Cancer 10, 781–791 (2024).
Article CAS PubMed Google Scholar
Chen, A. et al. Tumor genomic profiling practices and perceptions: a survey of physicians participating in the NCI-MATCH trial. JCO Precis. Oncol. https://doi.org/10.1200/PO.20.00217 (2020).
Comments (0)